SciSparc vs China SXT Pharmaceuticals
SPRC and SXTC side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How SPRC and SXTC compare
SciSparc grew revenue faster over the last twelve months (−34.5% versus −34.6% for China SXT Pharmaceuticals).
China SXT Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of −545% compared with −1423% at SciSparc.
China SXT Pharmaceuticals scores higher on the StockData Score (4 against 3 for SciSparc), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | SPRC | SXTC |
|---|---|---|
| Size and price | ||
| Share price | $0.355 | $2.73 |
| Change, 1 year | −98.6% | −100.0% |
| Change, 5 years | −100.0% | −100% |
| Beta (5Y) | 0.30 | – |
| Employees | 3 | 56 |
| StockData Score | ||
| Total score | 3 | 4 (better) |
| Valuation score | 0 | 0 |
| Growth score | 1 | 1 |
| Performance score | 0 | 1 (better) |
| Health score | 2 | 2 |
| Dividend score | 0 | 0 |
| Growth | ||
| Revenue growth (TTM) | −34.5% (better) | −34.6% |
| Revenue growth, 5Y average | – | −24.9% |
| EPS growth (TTM) | −51.9% | – |
| EPS growth, 5Y average | 36.4% | – |
| Profitability | ||
| Gross margin | 73.7% (better) | 21.9% |
| Operating margin | −978% | −626% (better) |
| Net margin | −1423% | −545% (better) |
| Return on equity | −770% | −27.5% (better) |
| Return on invested capital | – | −1657% |
| Financial health | ||
| Debt / equity | 0.09 | 0.03 (better) |
| Interest coverage | −1.0× (better) | −113.1× |
| Current ratio | 0.87 | 7.93 (better) |
| Piotroski F-score | 3 | 3 |
| Ownership | ||
| Held by insiders | 15.6% | 0.00% |
| Insider net buying, 12 months | −$4.6K | – |
| Short interest, % of float | 22.5% | 2.9% |
Go deeper
- SPRC stock overview
- SPRC income statement
- SPRC valuation and score
- SXTC stock overview
- SXTC income statement
- SXTC valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.